Veterans residing with advanced cancer will now have entry to complete genomic profiling. Foundation Medicine introduced that it has gained a federal contract from the Department of Veterans Affairs Nationwide Precision Oncology Program. The contract covers all of Foundation Medicine’s checks, together with FoundationOne CDx and FoundationOne Liquid for solid tumors and FoundationOne Heme for hematological malignancies.
CMS finalized protection for FoundationOne CDx in March 2018. Utilizing subsequent-era sequencing checks like CDx may help decide an affected person’s candidacy for scientific trials when no therapies can be found for his or her most cancers mutation
FoundationOne Liquid is the newest from the corporate. The check analyzes 70 genes identified to drive most cancers development to tell using checkpoint inhibitors and some focused therapies, comparable to poly (ADP-ribose) polymerase (PARP) inhibitors. The check grew to become commercially out there in the USA in September 2018.
In April 2018, FoundationOne Liquid was granted a Breakthrough Device designation by the FDA. Whether it is permitted, the check can be the primary FDA-authorised liquid biopsy take a look at to include some companion diagnostics and some biomarkers to tell the usage of focused oncology therapies. The check is an expanded model of the corporate’s earlier liquid biopsy takes a look at, FoundationACT.